Aviado · Research
Longevity Daily
Friday, October 30, 2026
Listen
Today's Brief
Population-level data shows that addressing 14 modifiable risk factors — from high blood pressure to hearing loss — could prevent nearly half of all dementia cases worldwide, making this today's clearest and most actionable finding. In research, Cell challenges the prevailing explanation for why calorie restriction extends life, while Aging Cell reports a brain-derived signal that slows whole-body aging in mice. Eli Lilly's retatrutide outpaces Ozempic two-to-one in a 1,298-person Phase 3 diabetes trial, and our Aviado deep-dive explains why curcumin's Nrf2 mechanism puts it a step ahead of most longevity supplements.
10 stories3 peer-reviewed1 trials1 Aviado original
Cognitive Health & Neuroprotection
14 Modifiable Risk Factors Could Prevent Nearly Half of All Dementia Cases Worldwide
If there's one number worth memorizing in brain health, it's 45%: that's the share of dementia cases that could be prevented or delayed by tackling 14 modifiable risk factors, including hypertension, hearing loss, diabetes, and physical inactivity, according to analysis drawing on Lancet Commission evidence — one of the most robust bodies of dementia research available. Unlike supplements or experimental drugs, every factor on the list is addressable today: manage your blood pressure, get your hearing tested, keep moving, and stay socially engaged. Prevention, it turns out, isn't a consolation prize — for most people it remains the single most powerful lever available. This piece lays out the evidence clearly and without hype.
Read more →Brain Scans Can't Tell You How Well You Regulate Emotions, 2,175-Person Study Finds
A large study led by the Central Institute of Mental Health (CIMH) finds that how active your prefrontal cortex looks on a brain scan tells you almost nothing about how effectively you regulate your emotions through cognitive reappraisal. This challenges a widely held assumption in neuroimaging research — and matters if you've seen brain activation marketed as a measure of emotional resilience or psychological fitness. Population-level correlations between brain regions and behaviors don't translate cleanly to individual predictions.
Read more →Scientists Watch Human Cells Grow 60 Years Younger — Gradually, Over 100 Days
Researchers at the University of Bonn have reversed approximately 60 years of cellular aging in human cells using a gradual approach that unfolds over more than 100 days — giving scientists an unprecedented window to watch rejuvenation unfold in real time. Published in Aging Cell, the method is slower than previous reprogramming techniques by design: the slower pace lets researchers identify precisely what drives and stalls the rejuvenation process. The long-term goal is new treatments for Alzheimer's and other age-related diseases, though human clinical applications remain years away.
Read more →Supplements & Compounds
Curcumin Doesn't Just Fight Free Radicals — It Makes Your Cells Better at Fighting Them
Curcumin's most important longevity mechanism isn't neutralizing free radicals directly — it's activating the Nrf2 transcription factor, which signals your cells to ramp up production of their own glutathione, superoxide dismutase, and catalase. Meta-analyses of randomized controlled trials confirm this effect is measurable, particularly with high-bioavailability formulations, though most evidence focuses on biomarker shifts rather than hard clinical endpoints. For those tracking antioxidant status, the practical starting point is 250–1,000 mg daily of an enhanced-absorption extract such as BCM-95 or Meriva.
Read the full Aviado analysis →Multivitamins Reliably Raise B-Vitamin Levels — But the Health Benefits Are Murkier
A scoping review of 157 clinical trial reports confirms that multivitamins consistently boost circulating folate, vitamin B6, and vitamin B12 — but whether those higher levels translate to meaningful health outcomes varies considerably by formulation, population, and baseline nutritional status. If you're already well-nourished, the evidence for broad clinical benefit is thin; the clearest case for multivitamins remains people with genuine deficiencies. Don't confuse moving a blood marker with improving a health outcome.
Read more →Research & Papers
Calorie Restriction Lowers DNA Mutation Rates — But That Doesn't Fully Explain Why It Extends Life
A new analysis published in Cell finds that calorie restriction does reduce the rate of DNA mutation accumulation — but not in proportion to the degree of lifespan extension it produces. This unsettles one of the leading mechanistic explanations for CR's longevity benefits, suggesting that mutation reduction alone can't account for the full effect. The findings raise important new questions about which downstream pathways CR is actually targeting — and what that means for drugs designed to mimic it.
Read more →A Brain-Derived Signal Slows Whole-Body Aging in Mice — Not Just the Brain
Researchers publishing in Aging Cell found that boosting fibroblast growth factor 13 (FGF13) in astrocytes — the brain's primary support cells — slows aging throughout the entire bodies of mice, not only in the nervous system. The finding adds to growing evidence that the brain may coordinate systemic aging through secreted signaling molecules, making astrocytes a compelling intervention target. This is a mouse study and needs human replication, but FGF13 joins a short list of brain-to-body longevity signals worth tracking.
Read more →Lifestyle & Nutrition
The CEO Behind Grand Theft Auto Trains Twice a Day — and Thinks Peptides Are Overhyped
Strauss Zelnick, CEO of Take-Two Interactive, has built one of the more rigorous longevity protocols in the business world — and he's pointedly skeptical of trendy interventions like peptide therapy and unproven supplements. He specifically calls out Harvard professor David Sinclair's advocacy for resveratrol and NMN as examples of bold promises outrunning the evidence. It's a useful counterweight to the biohacking hype cycle: the most battle-tested longevity tools — consistent resistance training, quality sleep, and solid nutrition — still outperform the newest additions to the stack.
Read more →Industry & Policy
Lilly's Retatrutide Delivers Twice Ozempic's Weight Loss in Phase 3 Diabetes Trial
In the TRANSCEND-T2D-2 Phase 3 trial of 1,298 adults with poorly controlled type 2 diabetes, Eli Lilly's triple agonist retatrutide produced more than double the weight loss of Ozempic (semaglutide 2 mg) in a head-to-head comparison. The tradeoff: more patients discontinued retatrutide due to side effects. For those tracking GLP-1s as metabolic health and longevity tools, retatrutide represents a meaningful step up in efficacy — tolerability will determine how broadly it gets adopted.
Read more →Bryan Johnson's Blueprint Brings Longevity Meal Kits to Tovala's Smart Oven Platform
Blueprint — Bryan Johnson's longevity product brand — has partnered with smart-oven meal service Tovala to launch a line of longevity-focused meals built around lean proteins, healthy fats, and nutrient-dense ingredients, free from dairy, refined sugars, artificial preservatives, hydrogenated oils, and more than 100 other flagged ingredients. The deal is notable as a signal that longevity protocols are migrating from niche supplement stacks into the mainstream consumer food market. Whether Blueprint's rigorous protocols translate meaningfully into a meal-kit format is a fair question — but the ingredient standards are hard to argue with.
Read more →